For help on how to get the results you want, see our search tips.
330 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Categories
Human Remove Human filter
Authorisation status
Withdrawn Remove Withdrawn filter
-
List item
Human medicine European public assessment report (EPAR): IntronA
interferon alfa-2b, Carcinoid Tumor; Leukemia, Hairy Cell; Lymphoma, Follicular; Hepatitis B, Chronic; Hepatitis C, Chronic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; Multiple Myeloma
Date of authorisation: 09/03/2000, Revision: 34, Withdrawn, Last updated: 15/12/2022 -
List item
Human medicine European public assessment report (EPAR): Macugen
pegaptanib, Wet Macular Degeneration
Date of authorisation: 31/01/2006, Revision: 15, Withdrawn, Last updated: 02/12/2022 -
List item
Human medicine European public assessment report (EPAR): Zynteglo
Autologous CD34+ cell enriched population that contains haematopoietic stem cells transduced with lentiviral vector encoding the βA-T87Q-globin gene, beta-Thalassemia
Date of authorisation: 29/05/2019,
, 
, 
, Revision: 5, Withdrawn, Last updated: 30/11/2022
-
List item
Human medicine European public assessment report (EPAR): Temybric Ellipta
fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 12/06/2019,, Revision: 4, Withdrawn, Last updated: 24/11/2022
-
List item
Human medicine European public assessment report (EPAR): Glubrava
metformin hydrochloride, pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 11/12/2007, Revision: 19, Withdrawn, Last updated: 18/10/2022 -
List item
Human medicine European public assessment report (EPAR): Glidipion (previously Pioglitazone Actavis Group)
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 15/03/2012,
, Revision: 8, Withdrawn, Last updated: 17/10/2022
-
List item
Human medicine European public assessment report (EPAR): Glustin
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 11/10/2000, Revision: 28, Withdrawn, Last updated: 17/10/2022 -
List item
Human medicine European public assessment report (EPAR): Zalviso
sufentanil, Pain, Postoperative
Date of authorisation: 18/09/2015, Revision: 7, Withdrawn, Last updated: 27/09/2022 -
List item
Human medicine European public assessment report (EPAR): Pioglitazone Teva Pharma
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 26/03/2012,, Revision: 13, Withdrawn, Last updated: 30/08/2022
-
List item
Human medicine European public assessment report (EPAR): Zynquista
Sotagliflozin, Diabetes Mellitus, Type 1
Date of authorisation: 26/04/2019,, Revision: 3, Withdrawn, Last updated: 16/08/2022
-
List item
Human medicine European public assessment report (EPAR): Thymanax
Agomelatine, Depressive Disorder, Major
Date of authorisation: 19/02/2009,
Date of refusal: 18/11/2006, Revision: 24, Withdrawn, Last updated: 08/08/2022 -
List item
Human medicine European public assessment report (EPAR): Episalvan
Betulae cortex, Wounds and Injuries; Wound Healing
Date of authorisation: 14/01/2016, Revision: 7, Withdrawn, Last updated: 15/07/2022 -
List item
Human medicine European public assessment report (EPAR): Crixivan
indinavir sulfate ethanolate, HIV Infections
Date of authorisation: 04/10/1996, Revision: 39, Withdrawn, Last updated: 12/07/2022 -
List item
Human medicine European public assessment report (EPAR): Senstend
lidocaine, prilocaine, Premature Ejaculation
Date of authorisation: 14/11/2019, Withdrawn, Last updated: 05/07/2022 -
List item
Human medicine European public assessment report (EPAR): Imatinib Actavis
imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Hypereosinophilic Syndrome; Dermatofibrosarcoma
Date of authorisation: 17/04/2013,, Revision: 13, Withdrawn, Last updated: 05/07/2022
-
List item
Human medicine European public assessment report (EPAR): Starlix
nateglinide, Diabetes Mellitus, Type 2
Date of authorisation: 03/04/2001, Revision: 15, Withdrawn, Last updated: 28/06/2022 -
List item
Human medicine European public assessment report (EPAR): Rasilez HCT
aliskiren, hydrochlorothiazide, Hypertension
Date of authorisation: 16/01/2009, Revision: 17, Withdrawn, Last updated: 20/05/2022 -
List item
Human medicine European public assessment report (EPAR): Docetaxel Zentiva (previously Docetaxel Winthrop)
docetaxel, Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 20/04/2007, Revision: 30, Withdrawn, Last updated: 20/05/2022 -
List item
Human medicine European public assessment report (EPAR): Pregabalin Mylan Pharma
pregabalin, Anxiety Disorders; Neuralgia; Epilepsy
Date of authorisation: 25/06/2015,, Revision: 7, Withdrawn, Last updated: 26/04/2022
-
List item
Human medicine European public assessment report (EPAR): Palonosetron Hospira
palonosetron hydrochloride, Nausea; Vomiting; Cancer
Date of authorisation: 08/04/2016,, Revision: 4, Withdrawn, Last updated: 08/04/2022
-
List item
Human medicine European public assessment report (EPAR): Skysona
elivaldogene autotemcel, Adrenoleukodystrophy
Date of authorisation: 16/07/2021,, Withdrawn, Last updated: 04/04/2022
-
List item
Human medicine European public assessment report (EPAR): Vivanza
vardenafil, Erectile Dysfunction
Date of authorisation: 04/03/2003, Revision: 28, Withdrawn, Last updated: 28/02/2022 -
List item
Human medicine European public assessment report (EPAR): Leganto
rotigotine, Restless Legs Syndrome; Parkinson Disease
Date of authorisation: 16/06/2011, Revision: 19, Withdrawn, Last updated: 18/02/2022 -
List item
Human medicine European public assessment report (EPAR): Staquis
Crisaborole, Dermatitis, Atopic
Date of authorisation: 27/03/2020,, Revision: 6, Withdrawn, Last updated: 08/02/2022
-
List item
Human medicine European public assessment report (EPAR): Atripla
efavirenz, emtricitabine, tenofovir disoproxil fumarate, HIV Infections
Date of authorisation: 13/12/2007, Revision: 36, Withdrawn, Last updated: 21/01/2022